Arctic Aurora LifeScience A NOK
Equity fund
1 year
USA
Largest region
Medium
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- Fondets målsetting er å øke verdien av andelseiernes investering gjennom å investere i aksjer globalt innenfor sektorer som farmasi, bioteknologi o.l.
Investment horizon
- Arctic Aurora LifeScience A NOK is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
07 Sept 2025
- Start date27 Nov 2016
- ISINIE00BYQ7ZL84
Risk
- Medium (4 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Annual cost
- Ongoing costs
Includes management fees of 2,00 %
- Platform fee
- Kickback fee
- Annual running costs
Other costs
- Performance-based fee
- Transaction costs
Costs for any currency exchanges are not included.
Allocation
- Stocks 95%Interest 5%
Portfolio
Shows the fund's largest investments.
- Eli Lilly and Co6.6%
- AstraZeneca PLC5.6%
- Alltrna, Inc -Series B Preferred Stock3.5%
- Novartis AG Registered Shares3.5%
- argenx SE3.4%
- BridgeBio Pharma Inc2.4%
- Soleno Therapeutics Inc2.4%
- BeOne Medicines Ltd ADR2.3%
- Daiichi Sankyo Co Ltd ADR2.2%
- Biothea Pharma Inc2.2%